Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors or Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2019
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Nivolumab (Primary) ; Vinblastine (Primary)
- Indications Glioma; Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms Metro-PD1
- 26 Mar 2019 Planned End Date changed from 1 Jul 2027 to 1 Jan 2028.
- 26 Mar 2019 Planned primary completion date changed from 1 Jan 2024 to 1 Jul 2024.
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.